Literature DB >> 26015935

CYP1A2 rs2069514 polymorphism and lung cancer susceptibility: a meta-analysis.

Wenlong Shao1, Jianxing He1.   

Abstract

Many studies have examined the association between the CYP1A2 rs2069514 polymorphism gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent. The PubMed was searched for case-control studies published up to Sep 01, 2014. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (CI) were calculated. In this meta-analysis, we assessed six published studies involving comprising 1,168 cases and 1,598 controls of the association between CYP1A2 rs2069514 polymorphism and lung cancer risk. For the homozygote A/A and A allele carriers (G/A + A/A), the pooled ORs were 1.47 (95% CI, 1.15-1.99; P=0.007 for heterogeneity) and 1.43 (95% CI, 1.07-1.90; P=0.000 for heterogeneity), when compared with the homozygous wild-type genotype (G/G). In the stratified analysis by ethnicity, the significantly risks were found among non-Asians for both the A allele carriers and homozygote A/A. However, no significant associations were found in Asian population all genetic models. These results from the meta-analysis suggest that CYP1A2 rs2069514 polymorphism contributes to risk of lung cancer among non-Asian population.

Entities:  

Keywords:  CYP1A2; lung cancer; meta-analysis; polymorphism; susceptibility

Year:  2015        PMID: 26015935      PMCID: PMC4430729          DOI: 10.3978/j.issn.2305-5839.2015.04.04

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  19 in total

1.  Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study.

Authors:  Sofia Pavanello; Ugo Fedeli; Giuseppe Mastrangelo; Federica Rota; Kim Overvad; Ole Raaschou-Nielsen; Anne Tjønneland; Ulla Vogel
Journal:  Cancer Genet       Date:  2012-06

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.

Authors:  Chee-Keong Toh; Fei Gao; Wan-Teck Lim; Swan-Swan Leong; Kam-Weng Fong; Swee-Peng Yap; Anne A L Hsu; Philip Eng; Heng-Nung Koong; Agasthian Thirugnanam; Eng-Huat Tan
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

Review 4.  Lung cancer molecular epidemiology in China: recent trends.

Authors:  Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2014-10

Review 5.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Authors:  Daniel W Nebert; Timothy P Dalton
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

6.  Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cDNA-expressed human CYP1A2.

Authors:  C L Miranda; Y H Yang; M C Henderson; J F Stevens; G Santana-Rios; M L Deinzer; D R Buhler
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

7.  CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population.

Authors:  Fatma B'chir; Sofia Pavanello; Jalel Knani; Sami Boughattas; Maurice J Arnaud; Saâd Saguem
Journal:  Life Sci       Date:  2009-03-28       Impact factor: 5.037

8.  A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Authors:  Shanbeh Zienolddiny; Daniele Campa; Helge Lind; David Ryberg; Vidar Skaug; Lodve B Stangeland; Federico Canzian; Aage Haugen
Journal:  Carcinogenesis       Date:  2008-02-06       Impact factor: 4.944

Review 9.  Cigarette smoking, metabolic activation and carcinogenesis.

Authors:  Akiyoshi Nishikawa; Yukio Mori; In-Seon Lee; Takuji Tanaka; Masao Hirose
Journal:  Curr Drug Metab       Date:  2004-10       Impact factor: 3.731

Review 10.  A comprehensive review of genetic association studies.

Authors:  Joel N Hirschhorn; Kirk Lohmueller; Edward Byrne; Kurt Hirschhorn
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.